FET-PET/MRI for Pituitary Tumors

Overseen By Julia Santos

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Mayo Clinic

Disqualifiers: MRI contraindications, Allergies to contrast, Severe medical conditions, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

5 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

Who Is on the Research Team?

Neetu Soni, MBBS, MD

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

I am a woman who can become pregnant and have a recent negative pregnancy test.

I am 18 to 75 years old and have been diagnosed with CD, Acromegaly, or tumor hyperprolactinemia.

* Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic Imaging

Participants undergo FET-PET/MRI to detect MRI-occult primary or residual/recurrent functional pituitary adenomas

1 week

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• [18F] Fluoroethyl-L-tyrosine

How Is the Trial Designed?

Group I: FET-PET/MRI Experimental Treatment 1 Intervention

Patients who desire surgery and have active Cushing's Disease, Acromegaly, or tumoral hyperprolactinemia, occult tumor on DCE-MRI

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+